Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) was $24.6 for the day, up 20.23% from the previous closing price of $20.46. In other words, the price has increased by $20.23 from its previous closing price. On the day, 56.44 million shares were traded. TEVA stock price reached its highest trading level at $25.0 during the session, while it also had its lowest trading level at $22.71.
Ratios:
Our analysis of TEVA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.74. For the most recent quarter (mrq), Quick Ratio is recorded 0.77 and its Current Ratio is at 1.06. In the meantime, Its Debt-to-Equity ratio is 2.57 whereas as Long-Term Debt/Eq ratio is at 2.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $24.
On May 28, 2025, Truist started tracking the stock assigning a Buy rating and target price of $25.
JP Morgan Upgraded its Neutral to Overweight on May 12, 2025, while the target price for the stock was maintained at $23.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 12 ’25 when Bridger Management, LLC (1) bought 95,000 shares for $19.89 per share.
McAvoy David R. bought 1,113 shares of TEVA for $20,988 on Sep 05 ’25. The EVP, Chief Legal Officer now owns 13,027 shares after completing the transaction at $18.86 per share. On Aug 01 ’25, another insider, Jover Placid, who serves as the See “Remarks” of the company, sold 6,053 shares for $15.16 each. As a result, the insider received 91,748 and left with 6,774 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TEVA now has a Market Capitalization of 28219914240 and an Enterprise Value of 38858706944. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.69 while its Price-to-Book (P/B) ratio in mrq is 4.13. Its current Enterprise Value per Revenue stands at 2.337 whereas that against EBITDA is 8.593.
Stock Price History:
The Beta on a monthly basis for TEVA is 0.70, which has changed by 0.16914284 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, TEVA has reached a high of $22.80, while it has fallen to a 52-week low of $12.47. The 50-Day Moving Average of the stock is 26.21%, while the 200-Day Moving Average is calculated to be 42.19%.
Shares Statistics:
TEVA traded an average of 10.05M shares per day over the past three months and 9440100 shares per day over the past ten days. A total of 1.15B shares are outstanding, with a floating share count of 1.15B. Insiders hold about 0.10% of the company’s shares, while institutions hold 63.21% stake in the company. Shares short for TEVA as of 1760486400 were 47284149 with a Short Ratio of 4.71, compared to 1757894400 on 55193262. Therefore, it implies a Short% of Shares Outstanding of 47284149 and a Short% of Float of 4.14.
Earnings Estimates
The dynamic stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.57, with high estimates of $0.59 and low estimates of $0.55.
Analysts are recommending an EPS of between $2.66 and $2.55 for the fiscal current year, implying an average EPS of $2.6. EPS for the following year is $2.78, with 11.0 analysts recommending between $2.88 and $2.68.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 6 analysts. It ranges from a high estimate of $4.63B to a low estimate of $4.33B. As of. The current estimate, Teva- Pharmaceutical Industries Ltd. ADR’s year-ago sales were $4.23BFor the next quarter, 6 analysts are estimating revenue of $4.01B. There is a high estimate of $4.07B for the next quarter, whereas the lowest estimate is $3.97B.
A total of 9 analysts have provided revenue estimates for TEVA’s current fiscal year. The highest revenue estimate was $17.17B, while the lowest revenue estimate was $16.87B, resulting in an average revenue estimate of $16.97B. In the same quarter a year ago, actual revenue was $16.54BBased on 10 analysts’ estimates, the company’s revenue will be $17.02B in the next fiscal year. The high estimate is $17.3B and the low estimate is $16.68B.
